Accordion title open
Show Description
Accordion title close
Close Description

SURPASS-2- Sustained a1c reductions at every dose vs. Ozempic chart

Percentage of Patients With A1C <7%1

ap<0.01 for superiority vs Ozempic 1 mg, adjusted for multiplicity.

Bar graph showing the percentage of adult patients with type 2 diabetes on metformin in the SURPASS-2 study who had an A1C of less than 7% at 40 weeks. The graph shows Mounjaro vs Ozempic 1 mg. From a mean baseline A1C of 8.3%, 82% (Mounjaro 5 mg, n=470), 86% (Mounjaro 10 mg, n=469), 86% (Mounjaro 15 mg, n=469), and 79% (Ozempic 1 mg, n=468) of patients had an A1C of less than 7%.